TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area.~* Subject has an Investigator's Global Assessment (IGA) score of at least three (moderate) at study start.~* If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study~Exclusion Criteria:~* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.~* Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start.~* Subject has used any systemic methotrexate, retinoids, systemic corticosteroids \[including intralesional, intra-articular, and intramuscular corticosteroids\], cyclosporine or analogous products within 90 days prior to study start.~* Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental therapy) within five half-lives of the biologic prior to study start.~* Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start or is intending to have such exposure during the study.~* Subject has used topical body (excluding the scalp) psoriasis therapy (including coal tar, anthralin, steroids, retinoids, vitamin D analogs) within 14 days prior to study start.~* Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start.~* Subject is currently using lithium or Plaquenil (hydroxychloroquine).~* Subject is currently using a beta-blocking medication (e.g., propanolol) or angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized.~* Subject is pregnant, lactating, or is planning to become pregnant during the study.~* Subject is currently enrolled in an investigational drug or device study.~* Subject has used an investigational drug or investigational device treatment within 30 days prior to study start.~* Subject has been previously enrolled in this study and treated with a test article.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Arm (Type: EXPERIMENTAL): Topical lotion, applied twice daily
- Vehicle Arm (Type: PLACEBO_COMPARATOR): Topical lotion, applied twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 18 years or above~2. Subjects must be diagnosed with cancer.~3. Subjects must experience persistent pain associated with cancer, and the pain score assessed by NRS should be \<4 within 1week before screening.~4. In the past 7 days, the subject must experience an average of 1 to 4 episodes of breakthrough cancer pain per day,The breakthrough cancer pain score should be ≥4 assessed by NRS~5. ECOG status of 0 to 2.~6. Subjects must consent to take adequate contraception during the study and 1 months after the study. Women of childbearing potential must show negative in the pregnancy test before dosing.~7. The subject must be able to understand the requirements of the study and provide a written informed consent.~Exclusion Criteria:~1. History or suspected allergies to fentanyl.~2. HGB \< 80 g/L, NEUT ≤1.0 × l09/L, PLT ≤50 × l09/L；ALT and AST higher than 3 times of ULN;total bilirubin and Cr higher than 1.5 times of ULN;PaO2 \<95%;FEV1/FVC\<70% and FEV1 accounted for less than 80% of the predicted value.~3. Any uncontrolled disease (e.g., severe mental, neurological, infectious, cardiovascular, respiratory and other systemic diseases).~4. Tumor infiltration to central nervous system.~5. Subjects are not able to slef evaluate pain intensity using NRS~6. Receive surgery in past 3 weeks~7. Treatment with any form of radiotherapy winth 1week prior to study entry that could alter pain or response to pain medication.~8. Taking monoamine oxidase inhibitors(MAOIs), CYP3A4 inhibitors or inducers within 14 days of the screening~9. Participated in other clinical trials in past 1months.~10. Pregnancy and breast-feeding women, women of childbearing age ready to conceive, and pregnancy test positive.~11. Other conditions that may affect the informed consent, compliance with the protocol, study results and safety of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled fentanyl aerosol (Type: EXPERIMENTAL): Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with Inhaled fentanyl aerosol (25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25µg) in a random sequence
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥20 years old~* Diagnosed with Type 2 diabetes mellitus at least 3 months before screening~* HbA1c of ≥7.0% and ≤10.0% (monotherapy group)~* HbA1c of ≥7.0% and ≤10.5% (combination therapy group)~Exclusion Criteria:~* Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus~* Past or current history of severe diabetic complications~* Fasting plasma glucose \> 270 mg/dL before treatment start~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients requiring insulin therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TA-7284-Low (Type: EXPERIMENTAL): None
- TA-7284-High (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of nasopharyngeal carcinoma WHO type II or III~  * Stage I-IV disease~ * Newly diagnosed disease~* Performance status~  * Patients ≤ 16 years of age: Lansky 60-100%~ * Patients \> 16 years of age: Karnofsky 60-100%~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min~* Creatinine based on age/gender as follows:~  * No greater than 0.4 mg/dL (for patients 1 month to \< 6 months of age)~ * No greater than 0.5 mg/dL (for patients 6 months to \< 1 year of age)~ * No greater than 0.6 mg/dL (for patients 1-2 years of age)~ * No greater than 0.8 mg/dL (for patients \< 6 years of age)~ * No greater than 1.0mg/dL (for patients 6 to \< 10 years of age)~ * No greater than 1.2 mg/dL (for patients 10 to \< 13 years of age)~ * No greater than 1.4 mg/dL (for female patients 13 to ≥ 16 years of age)~ * No greater than 1.5 mg/dL (for male patients 13 to \< 16 years of age)~ * No greater than 1.7 mg/dL (for male patients ≥ 16 years of age)~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age~* AST or ALT \< 2.5 times ULN for age~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Stratum I (radiotherapy, chemoprotective agent) (Type: EXPERIMENTAL): Patients undergo radiotherapy 5 days a week for 8 weeks. Patients also receive amifostine subcutaneously on the same days they undergo radiotherapy.
- Stratum II (chemotherapy, chemoprotective agent, radiotherapy) (Type: EXPERIMENTAL): Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completely resected histologically confirmed high-risk \[Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.~* Surgically rendered free of disease no more than 12 weeks before randomization.~* Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~* Adequate hematologic, hepatic, renal and cardiac function.~Key Exclusion Criteria:~* Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases.~* Evidence of distant metastatic disease.~* Prior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed.~* History of another malignancy or concurrent malignancy including prior malignant melanoma. Exceptions to this include: Patients who have been disease-free for 5 years or patients with a history completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ, multiple primary melanomas, or other malignancies for which the patient has been disease free for \> 5 years.~* History or current evidence of cardiovascular risk.~* History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib and trametinib (Type: EXPERIMENTAL): Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
- Dabrafenib and trametinib placebos (Type: PLACEBO_COMPARATOR): Subjects received matching placebos orally for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 to 18 months on the day of inclusion~* Informed consent form signed by the parent/legally acceptable representative and by an independent witness if requested by local Ethics Committee regulation or/and if the parent/legally acceptable representative is illiterate~* Child having completed the three-dose primary vaccination of Prevnar® in the hexavalent combined vaccine study (study A3L12).~* Subjects and parent/guardian able to attend all scheduled visits and comply with all study procedures~Exclusion Criteria:~* Participation in another clinical study investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the study vaccination~* Planned participation in another clinical study during the present study period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccine or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with study conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the study vaccination~* Planned receipt of any vaccine in the 4 weeks preceding or following study vaccination~* History of seizures Known personal Human Immunodeficiency Virus (HIV), Hepatitis B (HB) antigen or Hepatitis C seropositivity~* History of pneumococcal infection (confirmed either clinically, serologically or microbiologically)~* Previous booster vaccination against the pneumococcal disease with either the study vaccine(s) or another vaccine~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination~* Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Pneumo 23
- Group B (Type: ACTIVE_COMPARATOR): Prevnar

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnostic criteria for insomnia~* Diagnosis of obstructive sleep apnea (AHI \> or = 15) and prescription of PAP therapy~* Age \> or =50~* Community-dwelling~* Live within a 30-mile radius of VA GLAHS~* Have transportation to VA GLAHS to attend the intervention/control programs~Exclusion Criteria:~* Significant cognitive impairment (MMSE \< 24)~* History of mania, major psychopathology or a psychiatric hospitalization in prior two years

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral treatment (Type: EXPERIMENTAL): Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
- Active control (Type: ACTIVE_COMPARATOR): Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients, aged from 18 - 60, male or female, with wet wounds or burns, ulcerative skin and soft tissue wound surfaces;~2. The wound surface area ranged from 20cm\^2 to 600cm\^2;~3. The patients had a clear mind and there was no misunderstanding;~4. The patients voluntarily signed the subjects' informed consent form and received timely follow-ups.~Exclusion Criteria:~1. Patients with active bleeding in wound surfaces;~2. Vasogenic diseases: patients with no blood supply or phlebothrombosis in local wound tissues;~3. Those allergic to silk materials;~4. Those with serious infection;~5. Those with coagulation disorders;~6. Those with tumors or diabetes;~7. Patients who, according to other doctors' opinion, are unsuitable to use this material for wound treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- HQ® Matrix Medical Wound Dressing (Type: EXPERIMENTAL): After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
- Sidaiyi® wound dressing (Type: ACTIVE_COMPARATOR): After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Subjects Greater Than 40 Years of Age With COPD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medical diagnosis of COPD~* Current or prior history of cigarette smoking~Exclusion Criteria:~* Medical diagnosis of asthma~* Significant condition or disease other than COPD

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Systolic blood pressure ≥180 mm Hg on 2 consecutive readings(10 minutes apart)presenting in the emergency department (ED)~Exclusion Criteria:~* Use of any investigational drug within 1 month prior to emergency department (ED)~* Pregnant or breast-feeding females~* Contraindications or allergy to beta-blockers and calcium channel blockers (see FDA approved labeling for nicardipine intravenous and labetalol)~* Subjects with decompensated congestive heart failure (CHF) or with a known left ventricular ejection fraction (LVEF) \<35%~* History of stroke within 30 days~* Known liver failure~* Suspected myocardial infarction~* Suspected aortic dissection~* Suspected cocaine overdose~* Concurrently receiving other intravenous (I.V.) hypertensive medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): nicardipine intravenous
- 2 (Type: ACTIVE_COMPARATOR): Labetalol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* Admitted to Harborview Medical Center with injuries sufficiently severe to require inpatient admission~* Experienced a traumatic injury~* Exhibits symptoms of PTSD while in the hospital ward~Exclusion Criteria:~* History of head, spinal, or other injury that may prevent participation in the ward interview~* Requires immediate intervention due to conditions such as self-inflicted injury, active psychosis, or active mania~* Currently incarcerated~* Likely to face criminal charges~* Lives more than 50-100 miles from Harborview Medical Center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Stepped collaborative care (combination of behavioral therapy and drug therapy)
- 2 (Type: ACTIVE_COMPARATOR): Standard care provided to injured trauma survivors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete